Skip to main content

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

Recruiting · Phase 3 · NCT06439277

Conditions: Obesity, Weight Gain

At a glance

Research payments reported, 2025
$1.6M
U.S. investigators named
23
Sites paid
28
Planned or actual enrollment
300

About the trial

Sponsor
Eli Lilly and Company
Tested
Tirzepatide (drug), Placebo (drug)
Dates
Started 2024-06-03; completion 2030-12
Results posted
Not yet

The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits. Participants who have completed the primary 72-week GPIX study and have been off treatment for no more than 12 weeks (including the 4-week safety follow-up period), will have the opportunity to receive an additional 156 weeks of treatment with tirzepatide as well as continuing the lifestyle intervention.

From ClinicalTrials.gov, last updated 2026-09-24. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $1.6M in research payments for this study in 2025 (46 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.